Form 4: Schrodinger Executive Karen Akinsanya Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Karen Akinsanya, President of R&D, Therapeutics at Schrodinger, Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On April 14, 2025, Karen Akinsanya, President of R&D, Therapeutics at Schrodinger, Inc., executed stock options to acquire 13,378 shares at $3.22 and 3,345 shares at $2.92.
- Akinsanya then sold 8,378 shares at a weighted average price of $25.1123, 5,000 shares at a weighted average price of $25.1109, and 3,345 shares at $25.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on December 17, 2024.
- Following these transactions, Akinsanya directly owns 15,625 unvested RSUs and 18,970 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document simply reports stock transactions by an executive under a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Positives
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can provide transparency and avoid concerns about insider trading.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. The use of a 10b5-1 trading plan is a standard practice to allow insiders to sell shares without raising concerns about insider trading.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical and biotechnology industries often include stock options and restricted stock units (RSUs) to align management's interests with those of shareholders.
- The use of Rule 10b5-1 trading plans is a common practice among executives in publicly traded companies, including those in the biotechnology sector, such as Amgen, Gilead Sciences, and Vertex Pharmaceuticals, to manage their personal finances and diversify their holdings while avoiding potential insider trading accusations.
- The weighted average sale prices achieved by Akinsanya are within a typical range for stock sales by executives, reflecting the current market valuation of Schrodinger's stock.
Stakeholder Impact
- The stock sales could have a minor impact on shareholders by slightly increasing the supply of shares in the market.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2017/10/10 | Date stock option was granted. |
| 2018/08/03 | Date stock option was granted. |
| 2024/12/17 | Date the Rule 10b5-1 trading plan was adopted. |
| 2025/04/14 | Date of the reported transactions (exercise of options and sale of shares). |
| 2025/04/15 | Date of the signature on the Form 4 filing. |
| 2027/10/10 | Expiration date of stock option. |
| 2028/08/03 | Expiration date of stock option. |
Keywords
Schrodinger, Karen Akinsanya, Stock Options, Rule 10b5-1, Insider Trading, Form 4, SDGR, Shares, Sale, Purchase
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.